E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
sickle cell disease (SCD) |
anemia drepanocítica (AD) |
|
E.1.1.1 | Medical condition in easily understood language |
sickle cell disease (SCD) |
anemia drepanocítica (AD) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10040644 |
E.1.2 | Term | Sickle cell disease |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To assess the efficacy of FT-4202 in adolescents and adults with SCD as compared to placebo as measured by improvement in hemoglobin (Hb) • To assess the efficacy of FT-4202 as compared to placebo on the annualized vaso-occlusive crisis (VOC) rate |
•Evaluar la eficacia de FT-4202 en adolescentes y adultos con AD en comparación con placebo medida por la mejora de la hemoglobina (Hb). •Evaluar la eficacia de FT-4202 en comparación con placebo en la tasa anualizada de crisis vasooclusivas (CVO). |
|
E.2.2 | Secondary objectives of the trial |
• To measure the effects of FT-4202 on clinical measures and sequelae of hemolysis • To evaluate the effects of FT-4202 on the sequelae of VOC • To assess changes in fatigue of sickle cell patients taking FT-4202 |
•Medir los efectos de FT-4202 en las medidas clínicas y las secuelas de la hemólisis. •Evaluar los efectos de FT-4202 sobre las secuelas de las CVO. •Evaluar los cambios en la fatiga de los pacientes con anemia drepanocítica que toman FT-4202. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Provision of consent 2) Patient has a confirmed diagnosis of sickle cell disease 3) At least 2 episodes of vaso-occlusive crises in the past 12 months 4) Hemoglobin ≥ 5.5 and ≤ 10 g/dL (≥ 55 and ≤ 100 g/L) during screening 5) Patients taking hydroxyurea, must demonstrate a stable dose for at least 90 days prior to start of study treatment 6) Female patients of childbearing potential must use highly effective methods of contraception, male patients are willing to use barrier methods of contraception |
1) Prestación de consentimiento 2) El paciente tiene un diagnóstico confirmado de anemia de células falciformes. 3) Al menos 2 episodios de crisis vasooclusivas en los últimos 12 meses 4) Hemoglobina ≥ 5,5 y ≤ 10 g / dL (≥ 55 y ≤ 100 g / L) durante el cribado 5) Los pacientes que toman hidroxiurea deben demostrar una dosis estable durante al menos 90 días antes del inicio del tratamiento del estudio. 6) Las pacientes femeninas en edad fértil deben utilizar métodos anticonceptivos altamente eficaces, los pacientes masculinos están dispuestos a utilizar métodos anticonceptivos de barrera. |
|
E.4 | Principal exclusion criteria |
Medical Conditions 1) More than 10 vaso-occlusive crises within the past 12 months 2) Female who is breast feeding or pregnant 3) Hepatic dysfunction characterized by: - Alanine aminotransferase (ALT) > 4.0 × upper limit of normal (ULN) - Direct bilirubin > 3.0 × ULN 4) Known HIV positive 5) Active hepatitis B or hepatitis C infection 6) Severe renal dysfunction or on chronic dialysis 7) History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following: - Unstable angina pectoris or myocardial infarction or elective coronary intervention - Congestive heart failure requiring hospitalization - Uncontrolled clinically significant arrhythmias - Symptomatic pulmonary hypertension 8) History of overt clinical stroke within previous 2 years or any history of an intracranial hemorrhage Prior/Concomitant Therapy 1) Patients receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) 2) Receiving or use of concomitant medications that are strong inducers or moderate/strong inhibitors of CYP3A4/5 within 2 weeks of starting study treatment or anticipated need for such agents during the study 3) Use of voxelotor within 28 days prior to starting study treatment or anticipated need for this agent during the study 4) Use of a selectin antagonist (eg, crizanlizumab or other monoclonal antibody or small molecule) within 28 days of starting study treatment or anticipated need for such agents during the study 5) Use of erythropoietin or other hematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study 6) Receipt of prior cellular-based therapy (eg, hematopoietic cell transplant, gene modification therapy) |
Condiciones médicas 1) Más de 10 crisis vasooclusivas en los últimos 12 meses 2) Mujer que está amamantando o embarazada 3) Disfunción hepática caracterizada por: - Alanina aminotransferasa (ALT)> 4.0 × límite superior de lo normal (LSN) - Bilirrubina directa> 3,0 × LSN 4) VIH positivo conocido 5) Infección activa por hepatitis B o hepatitis C 6) Disfunción renal grave o en diálisis crónica 7) Historial de enfermedad cardíaca o pulmonar inestable o en deterioro dentro de los 6 meses anteriores al consentimiento, incluidos, entre otros, los siguientes: - Angina de pecho inestable o infarto de miocardio o intervención coronaria elective - Insuficiencia cardíaca congestiva que requiere hospitalización. - Arritmias clínicamente significativas no controladas - Hipertensión pulmonar sintomática 8) Historia de accidente cerebrovascular clínico manifiesto en los 2 años anteriores o cualquier historia de hemorragia intracraneal
Terapia previa / concomitante 1) Pacientes que reciben terapia de transfusión de sangre (RBC) programada regularmente (también denominada transfusión crónica, profiláctica o preventiva) 2) Recibir o usar medicamentos concomitantes que sean inductores fuertes o inhibidores moderados / fuertes de CYP3A4 / 5 dentro de las 2 semanas posteriores al inicio del tratamiento del estudio o la necesidad anticipada de dichos agentes durante el estudio. 3) Uso de voxelotor dentro de los 28 días anteriores al inicio del tratamiento del estudio o necesidad anticipada de este agente durante el estudio. 4) Uso de un antagonista de selectina (p. Ej., Crizanlizumab u otro anticuerpo monoclonal o molécula pequeña) dentro de los 28 días posteriores al inicio del tratamiento del estudio o la necesidad anticipada de dichos agentes durante el estudio. 5) Uso de eritropoyetina u otro tratamiento con factor de crecimiento hematopoyético dentro de los 28 días posteriores al inicio del tratamiento del estudio o la necesidad anticipada de dichos agentes durante el estudio. 6) Recepción de terapia celular previa (p. Ej., Trasplante de células hematopoyéticas, terapia de modificación genética) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Hb response rate at Week 24 (increase of > 1 g/dL [> 10 g/L] from baseline) during the blinded treatment period • Annualized VOC rate during the 52-week blinded treatment period based on adjudicated VOC review |
•Tasa de respuesta de la Hb en la semana 24 (aumento de >1 g/dl [>10 g/l] desde el inicio) durante el periodo de tratamiento enmascarado. •Tasa anualizada de CVO durante el periodo de tratamiento enmascarado de 52 semanas según la revisión de CVO adjudicada. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Hemoglobin response rate at Week 24 (increase of > 1 g/dL [> 10 g/L] from baseline) during the blinded treatment period [ Time Frame: 24 Weeks ] 2. Annualized vaso-occlusive crisis rate during the 52-week blinded treatment period based on adjudicated vaso-occlusive crisis review [ Time Frame: 52 Weeks ] |
1. Tasa de respuesta de la hemoglobina en la semana 24 (aumento de> 1 g / dL [> 10 g / L] desde el valor inicial) durante el período de tratamiento ciego [intervalo de tiempo: 24 semanas] 2. Tasa anualizada de crisis vasooclusiva durante el período de tratamiento ciego de 52 semanas según la revisión de crisis vasooclusiva adjudicada [intervalo de tiempo: 52 semanas] |
|
E.5.2 | Secondary end point(s) |
• Change from baseline in Hb at Week 24 during the blinded treatment period • Change in SCD-related clinical laboratory measurements from baseline at Week 24 during the blinded treatment period in: o % reticulocytes, o Unconjugated bilirubin, and o Lactate dehydrogenase (LDH) • Time to first VOC during the blinded treatment period • Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale at Week 24 during the blinded treatment period |
•Cambio con respecto al inicio en la Hb en la semana 24 durante el periodo de tratamiento enmascarado. •Cambio en las mediciones analíticas clínicas relacionadas con la AD con respecto al inicio en la semana 24 durante el periodo de tratamiento enmascarado en: o el porcentaje de reticulocitos, o la bilirrubina no conjugada y o la lactato deshidrogenasa (LDH). •Tiempo hasta la primera CVO durante el periodo de tratamiento enmascarado. •Cambio con respecto al inicio en la escala de fatiga del sistema de información de medición de resultados notificados por el paciente (PROMIS) en la semana 24 durante el periodo de tratamiento enmascarado. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Change from baseline in hemoglobin at W24 during the blinded treatment period [Time Frame: 24 Weeks] 2. Change in SCD related clinical lab measurements from baseline at W24 during the blinded treatment period [Time Frame: 24 Weeks] - % reticulocytes; Unconjugated bilirubin; Lactate dehydrogenase 3. Time to first vaso-occlusive during the blinded treatment period [Time Frame: 52 Weeks] 4. Change from baseline in PROMIS) Fatigue Scale at W24 during the blinded treatment period [Time Frame: 24 Weeks] Adult patients (18 to 65) will complete the PROMIS® Item Bank v.1.0 - Fatigue - Short Form 7a. Adolescent patients (12 to 17) will complete the PROMIS® Item Bank v2.0 - Fatigue - Short Form 10a. Responses are graded on a score of 1 to 5 with a higher score indicating a worse outcome. |
1. Cambio desde el valor inicial en la hemoglobina en la S24 durante el período de tratamiento cegado 2. Cambio en las mediciones de laboratorio clínico relacionadas con la SCD desde el inicio en la S24 durante el período de tratamiento ciego :% de reticulocitos;Bilirrubina no conjugada;Lactato deshidrogenasa 3. Tiempo hasta la primera vasooclusión durante el período de tratamiento ciego 4. Cambio desde el inicio en PROMIS) Escala de fatiga en S24 durante el período de tratamiento ciego Los pacientes adultos completarán el PROMIS® Item Bank v.1.0 - Fatiga - Short Form 7a. Los pacientes adolescentes completarán el PROMIS® Item Bank v2.0 - Fatiga - Short Form 10a. Las respuestas se califican con una puntuación de 1 a 5, y una puntuación más alta indica un resultado peor |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 29 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
United States |
France |
Germany |
Italy |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
última visita del ultimo paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |